Story
Amneal Pharma Shares Rise After FDA Approves Generic Drug for $983M Market
Summary
Amneal Pharmaceuticals received U.S. Food and Drug Administration approval for its generic Lanreotide Injection, a competitor to a branded drug with nearly $1 billion in annual sales, sending its stock price higher.
Amneal Pharmaceuticals (NASDAQ: AMRX) has received approval from the U.S. Food and Drug Administration (FDA) for its generic Lanreotide Injection, a development that grants the company access to a significant specialty drug market. The approval, announced on September 18, clears the product for immediate commercial launch.
Strategic Market Entry
The newly approved drug is a generic equivalent to Ipsen's Somatuline Depot, a branded treatment used for certain types of tumors. The market for this drug is substantial; according to a report from Investing.com, the branded version generated approximately $983 million in U.S. sales in the twelve months ending July 2026.
This approval allows Amneal to compete for a share of this lucrative market, representing a key strategic win for the company's generic drug portfolio. The launch builds on positive momentum from the company's second-quarter financial results, which included a revenue beat and raised full-year guidance to around $3.15 billion.
AdStock Performance and Valuation
Investors reacted positively to the news. On September 21, shares of Amneal Pharmaceuticals jumped 7.8% in a single session to close at $20.16. The stock's performance has been strong throughout the year, with a year-to-date gain of approximately 60%.
The recent rally has pushed the stock near the top of its 52-week range of $9.49 to $21.18. Amneal, a mid-cap company, currently has a market capitalization of between $6.5 billion and $7 billion, as noted in the source report.
Read next
More on Stocks
FTSE 100 Edges Higher as Record UK Borrowing Limits Fiscal Options
The UK's FTSE 100 index posted modest gains on Tuesday, even as new data revealed government borrowing hit a record for August, intensifying pressure on the Chancellor's fiscal plans ahead of the October budget.
European Stocks Edge Higher on Oil Price Relief as French Debt Concerns Mount
The pan-European STOXX 600 posted a modest gain as falling crude oil prices, driven by diplomatic signals at the UN, boosted sentiment. However, a sharp rise in the cost of insuring French government debt capped the market's advance.
Kingfisher Shares Surge on Profit Beat, Upgraded Guidance, and New Buyback
The UK-based home improvement retailer raised its full-year profit forecast after reporting better-than-expected interim results, driven by strong performance at its B&Q and Screwfix brands.
M&C Saatchi Shares Fall After First-Half Profit Plummets and Group Swings to Loss
Shares in M&C Saatchi plunged after the advertising group reported a nearly one-third drop in operating profit and a statutory pretax loss for the first half, citing significant restructuring costs and weaker revenue.